Breaking Finance News

A report released earlier today by Wedbush about Novan (VTX:NOVN) raises the target price to 27.00EUR

Novan (VTX:NOVN) had its price target upped to 27.00EUR by Wedbush in an issued report announced 10/17/2016. The new stock price target indicates a possible upside of 0.42% based on the company's last closing price.

Boasting a price of 18.97EUR, Novan (VTX:NOVN) traded 1.66% higher on the day. With the last stock price down -4.16% from the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same period. NOVN has recorded a 50-day average of 19.79EUR and a two hundred day average of 19.79EUR. Trade Volume was down over the average, with 48,278 shares of NOVN changing hands under the typical 370,128

Performance Chart

Novan (VTX:NOVN)

Novan has a with a 52 week low of 13.77EUR and a one year high of 23.79EUR NOVN’s market cap is currently 0 EUR.

About Novan (VTX:NOVN)

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *